Clinical Trial Update: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study evaluating HZN-1116 for Sjogren's Syndrome is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• HZN-1116

Snippet

Sponsor: Amgen | Conditions: Sjogren's Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING